Perspective on the Innovative Medicines Initiative 2 (IMI2)

Dr Ruxandra Draghia-Akli, MD PhD
Director Health
DG Research and Innovation
European Commission

IMI2 Open Info Day
Brussels, 30 September 2014
IMI2 is an integral part of our strategy for EU health research
Public-private partnerships
Investing together for next generation medicines and treatments

Public partnerships
Harnessing global expertise to fight poverty-related diseases

Global co-operation
One world, one team working to solve common health challenges

Collaborative research
Real-life solutions based on joint problem-solving
At the forefront

2003  EDCTP - 1st “Article 169 Initiative”

2008  IMI - 1st “Article 171 Initiative” at DG Research

2009  1st Joint Programming initiative on Alzheimer’s

2010  Innovation Partnerships on Active & Healthy Ageing

2010/11  Large-scale international research initiatives on Epigenome/Blueprint, rare diseases…

2012  “SMEs for Innovation” call & 1st Innovation Inducement Prize
**IMI2 scope and objectives**

- **IMI2 will expand the scope of IMI1 to cover the entire medical research and innovation value chain:**
  - Actively involve life science industries other than pharmaceuticals; for example the vaccine, the animal health or the biomedical imaging industry

- **Enable top quality research and innovations with great public health benefits and commercial possibilities**

- **Pave the way for the breakthrough vaccines, medicines and treatments which we will need in the near future:**
  - Develop new therapies for diseases with high unmet need, such as Alzheimer's disease, and limited market incentives, such as antimicrobial resistance
Priority Medicines for Europe and the World 2013 Update

Warren Kaplan, Veronika J. Wirtz, Aukje Mantel-Teeuwisse, Pieter Stoel, Béatrice Duthey, Richard Laing

9 July 2013

The right prevention and treatment for the right patient at the right time

Strategic Research Agenda for Innovative Medicines Initiative 2

Aligned with WHO priorities
IMI2 budget and funding

- Budget from public and private partners: 3.27 Billion Euro; 1.638 Billion Euro EU contribution:
  - Up to EUR 1 425 million to match EFPIA's contribution
  - Up to EUR 213 million to match additional contributions from other future Members or Associated Partners

- All EU funding goes to SMEs, medium-sized industrial partners (annual sales less than €500 million), academia, patient organisations and regulatory agencies

- Simplified funding rates & reporting (aligned with H2020)
How will IPR be handled?

Similarly to the first phase, IMI2 will aim to:

- Promote knowledge creation together with its disclosure and exploitation
- Achieve a fair allocation of rights
- Reward innovation
- Achieve a broad participation of private and public entities

IP rules only depart from H2020 rules when required by the specific operating needs of IMI2
IMI2 aligned with Horizon 2020

• Rules for participation apply, except for derogations on IPR and eligibility for funding

• Simplifications in Horizon 2020 also apply to IMI2 (funding rates, indirect cost!)

• Publication of calls on Participant Portal (and on IMI website)

• Search function includes IMI2 topics
Horizon 2020 Calls for Proposals

- Societal Challenges - Personalising health care
  - H2020-PHC-2015 single-stage RTD
  - Deadline: 24/02/2015
  - Opening Date: 30/07/2014

- Societal Challenges - Personalising health care
  - H2020-PHC-2015 two-stage
  - Deadline: 14/10/2014
  - Opening Date: 30/07/2014

- Societal Challenges - Health Coordination Activities
  - H2020-HCO-2015
  - Deadline: 24/02/2015
  - Opening Date: 30/07/2014

- Societal Challenges - IMI2 1st Call for Proposals 2014
  - H2020-ITI-IMI2-2014-01
  - Deadline: 12/11/2014
  - Opening Date: 09/07/2014

- Industrial Leadership - Horizon 2020 dedicated SME Instrument - Phase 1 2014
  - H2020-SMEINST-1-2014
  - Deadline: 18/06/2014
  - Opening Dates: 24/09/2014, 17/12/2014
  - Opening Date: 03/03/2014

Other Funding Opportunities

- Other EU Programmes 2014-2020
  - Research Fund for Coal & Steel
  - COSME
  - 3rd Health Programme
  - Consumer Programme
Keyword Search: Type 1 diabetes

1 Result

If you don't find your topic, you can also use the free text search.

Status: Open

Sort by:
- Title
- Call Id
- Public Date
- Deadline Date

Topic: Translational approaches to disease modifying therapy of Type 1 Diabetes Mellitus (T1DM): IMI2-2014-01-01

Specific challenge: Type 1 diabetes mellitus (T1DM) is a chronic disease affecting worldwide...

In addition, see all the open calls of Marie Skłodowska-Curie actions (MSCA) and European Research Council (ERC) grants for individual researchers of any nationality and research teams. The MSCA grants include opportunities for companies and SMEs. The MSCA and ERC grants are not restricted to specific topics.

Quick finder for topics linked to H2020 cross-cutting priorities:
- Cross-cutting Key-Enabling Technologies (KETS)
- ERA-NET
- Gender
- Contractual Public-Private Partnerships (PPPs)

International cooperation
SME Instrument
Social sciences and humanities

Call title: IMI2 1st Call for Proposals 2014
Call identifier: H2020-IMI2-2014-01

Deadline: 12-11-2014